Organ Dysfunction

Cabazitaxel

Description:

Cabazitaxel is a new taxoid, which promotes tubulin assembly and has shown strong antitumor activity against a broad spectrum of tumor models including those sensitive as well as resistant or refractory to other taxanes such as docetaxel. This is a Phase I safety and pharmacokinetic study of XRP6258 (Cabazitaxel) in advanced solid tumor patients with varying degrees of hepatic impairment.


Study Phase(s): Phase I
Category: Organ Dysfunction
Contact: Epp Goodwin at (210) 450-5798

Dasatinib

Description:

Dasatinib is an oral tyrosine kinase inhibitor of SRC family, BCR-ABL, c-kit, EPHA2 and PDGFß receptors. It is administered in advanced cancer patients with varying levels of liver dysfunction.


Type(s) of Cancer: Organ Dysfunction
Study Phase(s): Phase I
Category: Organ Dysfunction
Contact: Epp Goodwin at (210) 450-5798

Halaven

Description:

Halaven is a synthetic analogue of the marine spong natural product halichondrinB. As an inhibitor of microtubules it blocks the cell division and leads to apoptosis of the cancer cells. In this study Halaven is administered on days 1 and 8 of a 21 day cycle in patients with solid tumors who also have impaired renal function.


Type(s) of Cancer: Organ Dysfunction
Study Phase(s): Phase I
Category: Organ Dysfunction
Contact: Epp Goodwin at (210) 450-5798